[ad_1] Legislators in seven U.S. states are introducing psychedelics bills as they seek to emulate measures that have been approved in Oregon and Colorado. From state-regulated psychedelic therapy programs to the legalization of…
[ad_1] Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare IXHL announced that its Phase 2 clinical trial assessing proprietary psilocybin-assisted psychotherapy for Generalized Anxiety Disorder (GAD)…
[ad_1] Psychedelics therapy provider Field Trip Health & Wellness Ltd. launched a new online therapy offer with the goal of providing a combination of talk therapy, integrative wellness tools and insights derived…
[ad_1] Life sciences biotech company Cybin Inc. CYBN announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its…
[ad_1] After atai Life Sciences ATAI shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psychedelics biotech’s stocks plummeted. The closing stock price…
[ad_1] Red Light Holland Moves Full Speed Towards Canadian Controlled Drugs and Substances Dealer’s License Ontario-based magic mushrooms producer Red Light Holland Corp. TRUFF hired compliance consultants Cannabis License Experts…
[ad_1] Two psychedelics companies have shared their updates and key milestones to be reached this 2023. The 5-MeO-DMT Business Clinical-stage biopharma company GH Research PLC GHRS has received initial regulatory…
[ad_1] It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year. Cybin’s Programs For…
[ad_1] Psychedelics biopharma company Reunion Neuroscience Inc. REUN announced it is undertaking a Phase 1 clinical trial on RE104, which is a novel serotonergic substance that could treat postpartum depression. 32 healthy…
[ad_1] The new non-profit, Utah Mushroom Therapy, recently launched a campaign to support the legalization of magic mushrooms, also known as psilocybin. The move follows last February’s creation of a government task force to study…
[ad_1] Clinical-stage psychedelics biotech atai Life Sciences ATAI shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression…
[ad_1] MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therapy for…
[ad_1] Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. TRYPF shared the interim results for the first five patients dosed in its Phase 2 STOP (Study of the Treatment of Overeating utilizing…
[ad_1] The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs.…
[ad_1] Psychedelics R&D biotech Biomind Labs Inc. BMNDF has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 trial on…
[ad_1] The Minnesota Medical Association (MMA) has recently released a resolution calling for the removal of penalties for possession of small amounts of illicit drugs as well as promoting statewide…
[ad_1] The agency regulating all things related to psychedelic-assisted therapy (PAT), Health Canada released a notice to stakeholders on risk-management measures for clinical trials, a seemingly supporting move towards future government-supported…
[ad_1] Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Currently, in the form of a pill,…
[ad_1] Psychedelics company Clearmind Medicine Inc. CMND aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to…
[ad_1] Life sciences biotech Psyence Group Inc. PSYGF has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). The company issued more…
[ad_1] Psychedelics biotech Awakn Life Sciences Corp. AWKNF shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: Revenue of $314.827…
[ad_1] After a full review of healthcare provider Ehave Inc.‘s EHVVF IND application, the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with a clinical trial…
[ad_1] Part two of a three-part series. See previous story: Millennials Tipped The Scales In Colorado Voting, And Psychedelics Laws Are In Their Crosshairs Colorado’s approval of a measure decriminalizing the use,…
[ad_1] The DEA has shared its final production quotas for research drugs for 2023 and is now aiming for further manufacturing goals of several psychedelic compounds than the already substantial increases regarding…
[ad_1] British Colombia-based non-profit TheraPsil together with a group of patients and medical professionals from across Canada are headed to Ottawa to demand top health officials better access to medical psilocybin. The Canadian Controlled Drugs…